Crossmark

Association Between Antipsychotic Medication Use and Diabetes

Published Online: 2019-09-02

Published Print: 2019-10

Authors

Holt, Richard I. G.
Funding

Funding for this research was provided by:

University of Southampton
License Information

Text and Data Mining valid from 2019-09-02

Version of Record valid from 2019-09-02
More Information

Article History

First Online: 2 September 2019

Compliance with Ethical Standards

:

: Richard I.G. Holt received fees for lecturing, consultancy work and attendance at conferences from the following: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Lundbeck, Mylan, Novo Nordisk, Novartis, Otsuka, Sanofi, Sunovion, Takeda and MSD.

: The author is the chief investigator of the trial of 3 mg liraglutide in people with schizophrenia (UTN U1111-1203-0068; EudraCT: 2017-004064-35). All procedures in this study are performed in accordance with the ethical standards of the South Central - Hampshire B Research Ethics Committee (18/SC/0085) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Document is current